PrognosDx Health Granted Rights to University of California, Los Angeles (UCLA)'s Epigenetics Platform Technology
PALO ALTO, Calif.--(BUSINESS WIRE)--PrognosDx Health, Inc. announced the receipt of an exclusive, worldwide license to the patent rights associated with The University of California, Los Angeles (UCLA) technology discovered by Dr. Siavash K. Kurdistani, MD, Assistant Professor in the Department of Biological Chemistry, and Dr. David B. Seligson, MD, and colleagues at UCLA. The technology, based on the predictive power of global histone modification patterns, has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents.